Omeprazol IV

Phase 2Small molecule

UUniversidad Autonoma de Nuevo Leon

Omeprazol IV is one of 44 small molecule programs targeting Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseActive, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 3

—2

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 3

Viagra

VViatris Specialty LLC

Phase 3

1 4

Neurontin

VViatris Specialty LLC

Phase 3

1 5

Sandostatin

Sun Pharma

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Promacta

3 8

Retatrutide

Ozempic

1 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Liver Disease

NCT06861478

Clinical

Trials by Indication[1]

Liver Disease1 trial

PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease

Recruiting·UUniversidad Autonoma de Nuevo Leon·Phase 2·NCT06861478·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omeprazol IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omeprazol IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omeprazol IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Autonoma de Nuevo Leon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversidad Autonoma de Nuevo Leon

Omeprazol IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Liver Disease1 trial

References

Drug Info

Quick Facts

Related News